Search

Search Results

• 

  Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials

  Stefania Angela Di Fusco, Furio Colivicchi, Nadia Aspromonte, Marco Tubaro, Alessandro Aiello, Massimo Santini

  2017-05-18

  https://doi.org/10.4081/monaldi.2017.805

  2439

  PDF: 1182
• 

  Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by New Oral Anticoagulants, to be cautiously used

  Francesco Orso, Riccardo Barucci, Stefania Fracchia, Giulio Mannarino, Alessandra Pratesi, Francesco Fattirolli

  2013-12-30

  https://doi.org/10.4081/monaldi.2013.17

  1702

  PDF: 967

• Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thromboembolic risk

  Maurizio Giuseppe Abrignani, Furio Colivicchi

  2015-11-25

  https://doi.org/10.4081/monaldi.2013.80

  1108

  PDF: 704
• 

  Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation

  Giuseppe Patti, Ludmilla Mantione, Edoardo Bressi, Antonio Bisignani

  2018-06-07

  https://doi.org/10.4081/monaldi.2018.958

  4318

  PDF: 843

• Management strategies and choice of antithrombotic treatment in patients admitted with acute coronary syndrome - Executive summary for clinical practice

  Massimo Uguccioni, Francesco Pugliese, Leonardo De Luca, Marco Tubaro, Maria Pia Ruggieri, Furio Colivicchi

  2015-11-25

  https://doi.org/10.4081/monaldi.2013.86

  1252

  PDF: 753

• Critical issues in megatrials on new oral anticoagulants. Rocket AF: applying results to low risk patients

  Massimo Uguccioni, Cosimo Napoletano

  2015-11-25

  https://doi.org/10.4081/monaldi.2013.85

  992

  PDF: 638
• 

  Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation

  Lorenzo Palleschi, Eleonora Nunziata

  2018-06-07

  https://doi.org/10.4081/monaldi.2018.961

  3727

  PDF: 599

• From warfarin to new oral anticoagulants in clinical practice. What is the future of anticoagulant therapy in atrial fibrillation?

  Furio Colivicchi

  2015-11-25

  https://doi.org/10.4081/monaldi.2013.78

  751

  PDF: 701

• Rivaroxaban in non valvular atrial fibrillation: subgroups analysis

  Cesare Greco

  2015-08-19

  https://doi.org/10.4081/monaldi.2014.37

  1267

  PDF: 907

• Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part II: hemorrhagic risk and guidelines recommendations

  Maurizio Giuseppe Abrignani, Vincenzo Abrignani

  2015-11-25

  https://doi.org/10.4081/monaldi.2013.72

  1101

  PDF: 617

• Dual device intervention for stroke prevention and bradycardia: a case report

  Fulvio Cacciapuoti, Salvatore Crispo, Davide D’Andrea, Crescenzo Materazzi, Salvatore Chianese, Simona Cotena, Rossella Gottilla, Valentina Capone, Ciro Mauro

  2025-02-12

  https://doi.org/10.4081/monaldi.2025.3219

  449

  PDF_EARLY VIEW: 149

• Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments

  Andrea Segreti, Sara Mastroberardino, Lorenzo Frau, Alessandro Appetecchia, Luca D’Antonio, Danilo Ricciardi, Gian Paolo Ussia, Francesco Grigioni

  2024-05-02

  https://doi.org/10.4081/monaldi.2024.2882

  826

  PDF_EARLY VIEW: 365
• 

  COVID-19 and coagulative axis: review of emerging aspects in a novel disease

  Matilde Boccia, Luigi Aronne, Benito Celia, Grazia Mazzeo, Maria Ceparano, Vito D'Agnano, Roberto Parrella, Tullio Valente, Andrea Bianco, Fabio Perrotta

  2020-05-19

  https://doi.org/10.4081/monaldi.2020.1300

  5580

  PDF: 2877
• 

  SARS-CoV-2 induced coagulopathy and potential role of anticoagulation: Scoping review of literature

  Zehra Naseem, Muhammad Mussab Khakwani, Maaha Ayub, Ahmed Ayaz, Bushra Jamil, Ainan Arshad

  2022-01-26

  https://doi.org/10.4081/monaldi.2022.1958

  2021

  PDF: 886